BACKGROUND: To date, few randomized controlled trials (RCTs) of major depression have examined suicidal ideation as an outcome measure. Our aim is to determine the incidence of treatment-emergent suicidal ideation (ESI) and behaviors during the acute phase of treatment with an SSRI antidepressant or interpersonal psychotherapy (IPT) in patients with unipolar major depression. METHODS: In a two-site RCT, 291 adult outpatients with nonpsychotic major depression and a Hamilton Depression Rating Scale (HDRS) score ≥15 were randomly allocated to IPT or SSRI. Participants who did not remit with monotherapy received augmentation with the other treatment. ESI was defined as a post-baseline HDRS suicidality item score ≥2 or a post-baseline Quick Inventory of Depressive Symptomatology (QIDS) score ≥2 in patients with a baseline score ≤1. RESULTS: Of the 231 participants who had no suicidal ideation at baseline, 32 (13.8%) subsequently exhibited ESI on at least one post-baseline visit. Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT (HR = 2.21, 95% CI 1.04-4.66, P = .038), even after controlling for treatment augmentation, benzodiazepine use, and comorbidity with anxiety disorders. Worsening of suicidal ideation occurred in 7/60 patients who had suicidal ideation at baseline. In the large majority of cases, suicidal ideation was successfully managed with the study protocol. CONCLUSIONS: In the context of careful monitoring and frequent contact, selective serotonin reuptake inhibitor (SSRI) was associated with a lower risk of ESI than IPT and both SSRI and IPT appeared to be safe treatments for patients with past suicide attempts, none of whom exhibited ESI during the study.
RCT Entities:
BACKGROUND: To date, few randomized controlled trials (RCTs) of major depression have examined suicidal ideation as an outcome measure. Our aim is to determine the incidence of treatment-emergent suicidal ideation (ESI) and behaviors during the acute phase of treatment with an SSRI antidepressant or interpersonal psychotherapy (IPT) in patients with unipolar major depression. METHODS: In a two-site RCT, 291 adult outpatients with nonpsychotic major depression and a Hamilton Depression Rating Scale (HDRS) score ≥15 were randomly allocated to IPT or SSRI. Participants who did not remit with monotherapy received augmentation with the other treatment. ESI was defined as a post-baseline HDRS suicidality item score ≥2 or a post-baseline Quick Inventory of Depressive Symptomatology (QIDS) score ≥2 in patients with a baseline score ≤1. RESULTS: Of the 231 participants who had no suicidal ideation at baseline, 32 (13.8%) subsequently exhibited ESI on at least one post-baseline visit. Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT (HR = 2.21, 95% CI 1.04-4.66, P = .038), even after controlling for treatment augmentation, benzodiazepine use, and comorbidity with anxiety disorders. Worsening of suicidal ideation occurred in 7/60 patients who had suicidal ideation at baseline. In the large majority of cases, suicidal ideation was successfully managed with the study protocol. CONCLUSIONS: In the context of careful monitoring and frequent contact, selective serotonin reuptake inhibitor (SSRI) was associated with a lower risk of ESI than IPT and both SSRI and IPT appeared to be safe treatments for patients with past suicide attempts, none of whom exhibited ESI during the study.
Authors: E Frank; G B Cassano; P Rucci; W K Thompson; H C Kraemer; A Fagiolini; L Maggi; D J Kupfer; M K Shear; P R Houck; S Calugi; V J Grochocinski; P Scocco; J Buttenfield; R N Forgione Journal: Psychol Med Date: 2010-04-12 Impact factor: 7.723
Authors: M H Trivedi; A J Rush; H M Ibrahim; T J Carmody; M M Biggs; T Suppes; M L Crismon; K Shores-Wilson; M G Toprac; E B Dennehy; B Witte; T M Kashner Journal: Psychol Med Date: 2004-01 Impact factor: 7.723
Authors: Sidney Zisook; Madhukar H Trivedi; Diane Warden; Barry Lebowitz; Michael E Thase; Jonathan W Stewart; Christine Moutier; Maurizio Fava; Stephen R Wisniewski; James Luther; A John Rush Journal: J Affect Disord Date: 2009-02-14 Impact factor: 4.839
Authors: Ellen Frank; Giovanni B Cassano; Paola Rucci; Andrea Fagiolini; Luca Maggi; Helena C Kraemer; David J Kupfer; Bruce Pollock; Robert Bies; Vishwajit Nimgaonkar; Paul Pilkonis; M Katherine Shear; Wesley K Thompson; Victoria J Grochocinski; Paolo Scocco; Joan Buttenfield; Rocco Nicola Forgione Journal: Clin Trials Date: 2008 Impact factor: 2.486
Authors: T Petteri Sokero; Tarja K Melartin; Heikki J Rytsälä; Ulla S Leskelä; Paula S Lestelä-Mielonen; Erkki T Isometsä Journal: J Clin Psychiatry Date: 2003-09 Impact factor: 4.384
Authors: Roy H Perlis; Shaun Purcell; Maurizio Fava; Jesen Fagerness; A John Rush; Madhukar H Trivedi; Jordan W Smoller Journal: Arch Gen Psychiatry Date: 2007-06
Authors: Nader Perroud; Rudolf Uher; Andrej Marusic; Marcella Rietschel; Ole Mors; Neven Henigsberg; Joanna Hauser; Wolfgang Maier; Daniel Souery; Anna Placentino; Aleksandra Szczepankiewicz; Lisbeth Jorgensen; Jana Strohmaier; Astrid Zobel; Caterina Giovannini; Amanda Elkin; Cerisse Gunasinghe; Joanna Gray; Desmond Campbell; Bhanu Gupta; Anne E Farmer; Peter McGuffin; Katherine J Aitchison Journal: BMC Med Date: 2009-10-15 Impact factor: 8.775
Authors: Daniel C Mathews; Erica M Richards; Mark J Niciu; Dawn F Ionescu; Joseph J Rasimas; Carlos A Zarate Journal: Transl Neurosci Date: 2013-06 Impact factor: 1.757
Authors: Adrian I Campos; Enda M Byrne; Frank Iorfino; Chiara Fabbri; Ian B Hickie; Cathryn M Lewis; Naomi R Wray; Sarah E Medland; Miguel E Rentería; Nicholas G Martin Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2022-07-14 Impact factor: 3.358
Authors: Jaël S van Bentum; Suzanne C van Bronswijk; Marit Sijbrandij; Lotte H J M Lemmens; Frenk F P M L Peeters; Marjan Drukker; Marcus J H Huibers Journal: Depress Anxiety Date: 2021-03-23 Impact factor: 6.505